177 Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials.
In: Cancers, Jg. 14 (2022-12-15), Heft 24, S. 6022-6033
Online
academicJournal
Zugriff:
Simple Summary: Neuroendocrine Tumors are rare cancers with limited therapeutic options. Functioning NETs could produce bioactive peptides leading to a specific syndrome that impacts on patients' quality of life and also on survival—F-NETs patients who are refractory to SSA respond to 177LU-PRRT with a benefit in terms of prognosis. Introduction: Neuroendocrine tumors (NETs) are rare malignancies with different prognoses. At least 25% of metastatic patients have functioning neuroendocrine tumors (F-NETs) that secrete bioactive peptides, causing specific debilitating and occasionally life-threatening symptoms such as diarrhea and flushing. Somatostatin analogs (SSAs) are usually effective but beyond them few treatment options are available. We evaluated the clinical efficacy of 177 Lu-DOTATATE in patients with progressive metastatic F-NETs and SSA-refractory syndrome. Patients and Methods: A non-pre-planned joint analysis was conducted in patients enrolled in phase II clinical trials on metastatic NETs. We extrapolated data from F-NET patients with ≥1 refractory sign/symptom to octreotide, and ≥1 measurable lesion. Syndrome response (SR), overall survival (OS), progression-free survival (PFS), tolerance and disease response were analyzed. Results: Sixty-eight patients were enrolled, the majority (88.1%) with a SR. According to RECIST criteria, 1 (1.5%) patient showed a CR, 21 (32.3%) had a PR and 40 (61.5%) SD. At a median follow-up of 28.9 months (range 2.2–63.2) median PFS was 33.0 months (95%CI: 27.1–48.2). Median OS (mOS) had not been reached at the time of the analysis; the 2-year OS was 87.8% (95%CI: 76.1–94.1). Syndromic responders showed better survival than non-responders, with a 2-year OS of 93.9% (95%CI: 92.2–98.0) vs. 40.0% (95%CI: 6.6–73.4), respectively. A total of 233 adverse events were recorded. Grade 1–2 hematological toxicity was the most frequent. Conclusion: The 177 Lu-DOTATATE improved symptoms and disease control in patients with F-NETs. Treatment was well tolerated. The syndrome had an impact on both quality of life and OS. [ABSTRACT FROM AUTHOR]
Titel: |
177 Lu-DOTATATE Efficacy and Safety in Functioning Neuroendocrine Tumors: A Joint Analysis of Phase II Prospective Clinical Trials.
|
---|---|
Autor/in / Beteiligte Person: | Bongiovanni, Alberto ; Nicolini, Silvia ; Ibrahim, Toni ; Foca, Flavia ; Sansovini, Maddalena ; Di Paolo, Arianna ; Grassi, Ilaria ; Liverani, Chiara ; Calabrese, Chiara ; Ranallo, Nicoletta ; Matteucci, Federica ; Paganelli, Giovanni ; Severi, Stefano |
Link: | |
Zeitschrift: | Cancers, Jg. 14 (2022-12-15), Heft 24, S. 6022-6033 |
Veröffentlichung: | 2022 |
Medientyp: | academicJournal |
ISSN: | 2072-6694 (print) |
DOI: | 10.3390/cancers14246022 |
Schlagwort: |
|
Sonstiges: |
|